Healthcare / BiotechnologyParis
$8.57
+0.08 (+0.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-29.7M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$429M
P/E
N/A
•EV/EBITDA
N/A
•ROE
381.5%
↑Gross Margin
99.5%
↑Debt/Equity
-6.69
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+48.0%
FCF CAGR
—
FCF margin
-45.3%
FCF / Net income
0.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.4M · net income $-86.0M · FCF $-29.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.4M | $65.4M | $67.0M | $28.6M | $20.2M |
| Net Income | $-86.0M | $-86.0M | $1.5M | $-28.9M | $-23.7M |
| EBITDA | $-83.5M | $-83.5M | $8.3M | $-22.2M | $-17.6M |
| EPS | — | — | 0.03 | -0.58 | -0.48 |
| Gross Margin | 99.5% | 99.5% | 99.6% | 98.8% | 98.8% |
| Operating Margin | -81.9% | -81.9% | 4.8% | -95.1% | -135.3% |
| Net Margin | -131.4% | -131.4% | 2.2% | -101.2% | -117.4% |
| Balance Sheet | |||||
| Debt/Equity | -6.69 | -6.69 | 0.90 | 1.03 | 0.80 |
| Current Ratio | 2.00 | 2.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-29.7M | $-29.7M | $14.6M | $-57.9M | $-72.6M |
| Returns | |||||
| ROE | 381.5% | 381.5% | 2.2% | -42.5% | -25.1% |
| Valuation | |||||
| P/E | — | — | 119.67 | — | — |
| EV/EBITDA | — | — | 19.32 | — | — |
| P/B | — | — | 2.61 | 2.61 | 2.03 |
| Growth & Yield | |||||
| Revenue Growth | -2.3% | -2.3% | 134.6% | 41.4% | — |
| EPS Growth | — | — | 105.2% | -20.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+124.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.03 → n/d
Residual
+124.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.